Lipanthyl NT 145 mg/Lipanthyl Supra 160 mg/Lipanthyl 67 mg Dosage/Direction for Use

Response to therapy should be monitored by determination of serum lipid values. If an adequate response has not been achieved after several months (e.g. 3 months), complementary or different therapeutic measures should be considered.
Posology: Lipanthyl NT 145 mg: Adults: The recommended dose is one tablet containing 145 mg fenofibrate taken once daily. Patients currently taking one 200 mg capsule (or one 160 mg tablet) can be changed to one 145 mg fenofibrate tablet without further dose adjustment.
Lipanthyl Supra 160 mg: Adults: The recommended dose is one tablet containing 145 mg/160 mg fenofibrate taken once daily. Patients currently taking one 200 mg capsule (or one 160 mg tablet) can be changed to one 160 mg fenofibrate tablet without further dose adjustment.
Lipanthyl 67 mg: Adults: Micronized Formulations (MF): The recommended dose is 200 mg daily administered as three capsules of Fenofibrate (Lipanthyl) 67mg.
The dose can be titrated up to 4 capsules Fenofibrate (Lipanthyl) 67 mg if required.
Special populations: Geriatric population: In elderly patients, without renal impairment, the usual adult dose is recommended.
Renal impairment: Dosage reduction is required in patients with renal impairment. In moderate chronic kidney disease (creatinine clearance 30 to 60 mL/min), and if a low dose is available, start with one capsule of 100 mg standard or 67 mg micronized once daily.
If no low dose is available, then fenofibrate is not recommended.
In patients with severe chronic kidney disease (creatinine clearance < 30ml/min), fenofibrate is contraindicated.
Hepatic impairment: Fenofibrate is not recommended for use in patients with hepatic impairment due to the lack of data.
Pediatric population: Lipanthyl NT 145 mg/Lipanthyl Supra 160 mg: The safety and efficacy of fenofibrate in children and adolescents younger than 18 years has not been established. No data are available. Therefore the use of fenofibrate is not recommended in pediatric subjects under 18 years.
Lipanthyl 67 mg: The safety and efficacy of fenofibrate in children have not yet been established. Only limited pediatric data are available (see Pharmacology: Pharmacodynamics under Actions). Therefore the use of fenofibrate is not recommended in pediatric subjects under 18 years.
Method of administration: Lipanthyl NT 145 mg: Fenofibrate (Lipanthyl NT) 145 mg film-coated tablet may be given at any time of the day, with or without food (see Pharmacology: Pharmacokinetics under Actions). Fenofibrate (Lipanthyl NT) 145 mg film-coated tablet should be swallowed whole with a glass of water.
Lipanthyl Supra 160 mg: Fenofibrate (Lipanthyl Supra) 160 mg tablet should be swallowed whole during a meal.
Lipanthyl 67 mg: Fenofibrate (Lipanthyl) should be swallowed whole during a meal.